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Background: Comparison of diabetes remission rates after bariatric surgery using two different models of criteria.
Methods: Retrospective analysis of data from 110 patients with type 2 diabetes and morbid obesity who
underwent bariatric surgery, preoperatively and at 18-month follow-up. Comparison of two models of remission:
1) 2009 consensus statement criteria; 2) simple criteria using ADA’s HbA1c diabetes diagnostic cut-off values.
Results: Patients’ mean ± SD preoperative characteristics were: age 53.3 ± 9.5 years, BMI 43.6 ± 5.5 kg/m2, HbA1c
7.9 ± 1.8%, duration of diabetes 7.6 ± 7.5 years. 44.5% of patients with previous insulin therapy. With 2009
consensus statement criteria: complete, partial and no remission in 50%, 12.7% and 37.3%, respectively; with
HbA1c criteria: 50%, 15% and 34.5% in the analogous categories (p = 0.673).
Conclusions: We suggest a simpler approach to evaluate diabetes remission after bariatric surgery, following the
rationale of the definition of diabetes itself.
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Buse et al. [1] proposed in 2009 a consensus definition
of diabetes remission. These clear, although strict, cri-
teria prompt the need to reconsider diabetes remission
rates after bariatric surgery.
The objective of this study is to compare diabetes
remission rates using Buse’s consensus group criteria
with those obtained with a simpler definition based on
the American Diabetes Association’s (ADA) glycosylated
hemoglobin (HbA1c) cut-off levels used to diagnose dia-
betes [2], after bariatric surgery.
Methods
Data were retrospectively analyzed from a cohort of 539
patients who underwent bariatric surgery with a pre-
operative diagnosis of diabetes and morbid obesity (body
mass index [BMI] > 35 kg/m2) in a single center. Informa-
tion was obtained from medical records, preoperatively,
and at 18 months after surgery. Duration of diabetes,* Correspondence: marubioh@gmail.com
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distribution, and reproduction in any mediumprevious hypoglycemic treatment, age, weight, height,
BMI, fasting glucose (FG) and HbA1c were recorded.
All patients signed a written informed consent prior to
surgery in which it was specified that clinical and analyt-
ical data collected before the bariatric procedure and
during follow up could be potentially used in an an-
onymous way for investigation and publication. This
study was approved by the Ethics Committee of the
Hospital Clinico San Carlos and was in compliance with
the Helsinki Declaration.
Two criteria were used to define diabetes remission:
1) 2009 consensus statement (model 1): complete remis-
sion if “normal” measures of glucose metabolism were
achieved (HbA1c < 6% and FG < 100 mg/dl [< 5.6 mmol/l];
partial remission if HbA1c < 6.5% and FG 100–125 mg/dl
(5.6-6.9 mmol/l), in both cases in the absence of pharmaco-
logic therapy or ongoing procedures, for a duration of at
least one year [1]. 2) “HbA1c criteria”, based on HbA1c
levels used to define diabetes in current ADA guidelines
[2] (model 2): remission if HbA1c < 5.7%, improvement
if HbA1c 5.7 - 6.5%, in both cases without hypoglycemic
treatment and a duration of at least one year, and no
remission if these criteria were not met.tral Ltd. This is an Open Access article distributed under the terms of the
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samples collected with EDTA 3 K, by using high per-
formance liquid chromatography (HPLC) (Tosoh G8W).
This method is monthly evaluated by the Program of
External Guarantee of Quality of the Spanish Society of
Clinical Chemistry, and is in compliance with ADA rec-
ommendations [2], which specify that the diagnostic
test should be performed using a method that is certi-
fied by the National Glycohemoglobin Standardization
Program (NGSP).
Three types of bariatric surgery were performed: lap-
aroscopic Roux-en-Y gastric bypass, biliopancreatic di-
version and sleeve gastrectomy. Eligibility for each of
them varied according to the patients’ previous diabetes
medical history and comorbidities.
Preoperative features were compared with the 18-month
follow-up ones using t test for paired samples and
Wilcoxon’s test. The number of patients in each remis-
sion category 18 months after surgery using both cri-
teria was compared using Chi-square test. Preoperative
characteristics were evaluated in their association with
rates of the three remission categories with Kruskal
Wallis and Chi square tests.Results
We obtained data from 110 patients with type 2 diabetes
(61.8% women). Mean ± SD preoperative characteristics
were: age 53 ± 10 years, BMI 43.6 ± 5.5 kg/m2, FG 165.2 ±
58.5 mg/dL and HbA1c 7.9 ±1.8%. Mean duration of
diabetes was 7.6 ±7.5 years and 44.5% of patients were
on insulin therapy prior to surgery.Table 1 Patients’ characteristics according to each remission
Variable 2009 Consensus group criteri
TOTAL Complete Partial N
No of patients 110 55 (50.0) 14 (12.7)
Age (years) 53.3 ± 9.5 51.5 ± 9.8 55.6 ± 8.0
Preop - BMI (kg/m2) 43.6 ± 5.5 44.3 ± 5.2 43.7 ± 4.8
18 m - BMI (kg/m2) 29.0 ± 5.0 28.1 ± 4.5 31.8 ± 4.9
Preop – FG (mg/dl) 165.2 ± 58.5 156.0 ± 55.3 137.8 ± 26.6
18 m – FG (mg/dl) 100.2 ± 23.9 86.7 ± 7.5 104.6 ± 6.9
Preop - HbA1c (%) 7.9 ± 1.8 7.5 ± 1.5 7.0 ± 0.8
18 m - HbA1c (%) 5.4 ± 0.7 5.0 ± 0.6 5.5 ± 0.5
%WL 33.1 ± 9.4 36.1 ± 7.9 27.1 ± 7.2
%EWL 70.7 ± 21.0 75.9 ± 17.7 57.0 ± 15.3
Duration of diabetes (years) 7.6 ± 7.5 5.1 ± 4.0 4.4 ± 4.8
Previous treatment
with insulin
No 61 (55.5) 39 (70.9) 10 (71.4)
Yes 49 (44.5) 16 (29.1) 4 (28.6)
Values show mean ± SD or number of patients and percentages (%).
“Preop” = preoperative; “18 m” = 18-month; “BMI” = body mass index; “FG” = fasting
loss at 18 months; “%EWL” = percentage excess body weight loss at 18 months.At 18-months follow-up, mean ± SD BMI, FG and
HbA1c were 29.0 ± 5.0 kg/m2, 100.2 ± 23.9 mg/dL and
5.4 ± 0.7%, respectively, all being significantly different
from their corresponding preoperative values (p < 0.001
in all cases).
Eighteen months after bariatric surgery, according to
model 1, 50% obtained complete remission, 12.7% partial
remission, and 37.3% no remission. With model 2, rates
in the analogous categories were 50%, 15% and 34.5%,
respectively (Table 1). No significant differences were
found whichever the criteria used (p = 0.673). Age and
preoperative BMI did not influence the rate of remission.
Percentage of body weight loss (% WL) and percentage
of excess body weight loss (% EWL) were greater in
the complete remission group (p < 0.05). Mean dur-
ation of diabetes was significantly different across the
three remission categories (p = 0.001), being greater in
the non-remission group (p < 0.05). Previous insulin
treatment was more frequent in the non-remission
group (p = 0.000).
Discussion
This study revealed that using simpler criteria based
on ADA’s diabetes diagnostic HbA1c cut-off values [2]
(model 2) results in remission rates comparable to
those obtained with the criteria proposed by the 2009
consensus group [1] (model 1). We consider that model 2
criteria were more straightforward and of easy application,
as they are based on only one biochemical parameter (the
HbA1c level), in the absence of hypoglycemic treatment.
The use of Buse et al’s criteria has proved to achieve
lower remission rates after bariatric procedures [3],category
a (Model 1) ADA’s HbA1c criteria (Model 2)
o remission p <5.7% 5.7-6.5% >6.5% and/or
treatment
p
41 (37.3) 55 (50.0) 17 (15.5) 38 (34.5)
54.9 ± 9.4 0.230 52.1 ± 9.7 52.8 ± 8.4 55.2 ± 9.7 0.299
42.8 ± 6.0 0.514 44.1 ± 4.9 43.6 ± 6.2 43.0 ± 6.0 0.595
29.2 ± 5.4 0.049 28.3 ± 4.3 30.9 ± 6.0 29.3 ± 5.4 0.193
186.9 ± 64.3 0.004 153.9 ± 55.1 142.0 ± 29.5 191.8 ± 64.4 0.001
118.6 ± 30.4 0.000 87.7 ± 8.9 101.5 ± 12.4 119.8 ± 30.8 0.000
8.6 ± 1.9 0.002 7.3 ± 1.3 7.7 ± 1.8 8.7 ± 1.9 0.000
6.1 ± 0.6 0.000 4.9 ± 0.5 5.8 ± 0.1 6.1 ± 0.7 0.000
31.0 ± 10.4 0.001 35.6 ± 8.1 29.4 ± 8.3 31.0 ± 10.5 0.014
68.6 ± 24.4 0.007 74.9 ± 17.7 63.3 ± 22.5 68.0 ± 23.7 0.070
11.9 ± 9.9 0.001 5.3 ± 4.3 4.6 ± 3.5 12.6 ± 10.0 0.000
12 (29..3) 0.000 37 (67.3) 14 (82.4) 10 (26.3) 0.000
29 (70.7) 18 (32.7) 3 (17.6) 28/73.7)
glucose; “HbA1c” = glycosylated hemoglobin; “%WL” = percentage body weight
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compare the outcomes of studies. Buchwald et al. [4], in
3,188 patients with type 2 diabetes, reported a 56.7-95.1%
resolution rate, depending on the bariatric procedure used,
and defining remission as being off diabetes medications
with normal FG (< 100 mg/dl [< 5.6 mmol/l]) or HbA1c <
6%. The elevated remission rates remarked in this meta-
analysis and in other following studies [5,6] have generated
controversial and confounding expectations regarding
true remission rates for patients with type 2 diabetes
after bariatric surgery. In our series, at 18-month follow-
up, complete remission was achieved in 50% of patients,
in agreement with rates previously communicated [3,7,8].
Therefore, the need for uniform inclusion criteria to define
type 2 diabetes complete or partial remission after bariat-
ric surgery becomes evident and, for this reason, this issue
should be addressed by scientific societies and a consensus
should be reached in specific position statements.
It has recently been outlined [9,10] that diabetes dur-
ation, use of insulin, the bariatric procedure performed
and, presumably, preoperative BMI, all contribute to
the wide variability of remission rates reported. In the
present study, regardless of the model used, longer dur-
ation of diabetes and previous treatment with insulin,
were found to be associated with a lower rate of remis-
sion, a finding which is consistent with most published
analyses [9,11-13]. Knowledge of these previous factors
may be useful to determine how much improvement
can be potentially expected after a specific bariatric
procedure. For instance, in our series, in accordance to
what has recently been observed [8,10,14], remission
rates in patients previously on insulin therapy were
around 30%, whilst rates raised up to 70% in those
patients receiving only oral medication. Similarly, and
also agreeing with previous works [8,9], we observed
an inverse relation between diabetes duration and reso-
lution. Thus, in future studies, differences in remission rates
should be specified according to previous hypoglycemic
treatments and/or diabetes duration.Conclusions
In conclusion, we propose simpler criteria for diabetes
remission after bariatric surgery based on the ADA’s def-
inition of diabetes. These may be of a more practical and
affordable clinical application, as well as realistic regard-
ing what outcomes to expect.
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